Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present and host investor meetings at the following conferences:

Jefferies 2019 Global Healthcare Conference
Date: Thursday, June 6, 2019
Presentation Time: 4:30 PM ET
Location: Grand Hyatt in New York, NY

Raymond James Life Sciences and MedTech Conference
Date: Tuesday, June 18, 2019
Presentation Time: 4:10 PM ET
Location: Lotte New York Palace in New York, NY

JMP Securities Life Sciences Conference
Date: Wednesday, June 19, 2019
Presentation Time: 9:30 AM ET
Location: The St. Regis in New York, NY

A live webcast of the presentations can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is FDA-approved for the treatment of ocular pain following ophthalmic surgery. OTX-TP (intracanalicular travoprost insert) is an intracanalicular insert in Phase 3 clinical development for the reduction of intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension. The Company’s earlier stage assets include OTX-TIC, an extended-delivery intracameral travoprost implant for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal implants for the treatment of retinal diseases. These intravitreal implants include OTX-TKI, containing a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, OTX-IVT, an extended-delivery protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190530005119/en/

Investors
Ocular Therapeutix
Donald Notman
Chief Financial Officer
[email protected]

Media
Ocular Therapeutix
Scott Corning
Senior Vice President, Commercial
[email protected]
or
Westwicke, an ICR Company
Chris Brinzey, 339-970-2843
[email protected]

Source: Ocular Therapeutix, Inc.

You May Also Be Interested In

• Raymond James: 'we still are encouraged by this near-term opportunity for MGTX'
• Golden Spike Announces Closing of Non-Brokered Private Placement
• Tesoro Minerals Closes C$1 Million Private Placement